Authors
Latest:
Pharma Transparency in Brazil: Latest DevelopmentsScott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region.
Latest:
Relationship-Centric Technology: Improving the Human Experience for Better EngagementRelationship-centric technology presents a sizable emerging opportunity for sponsors to improve the performance of clinical development, writes Tom O' Leary.
Latest:
Opposites Attract: Pairing R&D and Commercial TeamsMeike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.
Latest:
Multiethnic Marketing: The Billion-Dollar UpsideTapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.
Latest:
Patient Adherence: Balancing High-Tech with High-TouchLoreen M. Brown discusses how technology has influenced how healthcare teams function, from leveraging and delivering care to interacting with patients throughout the patient journey.
Latest:
"There's a Cure for That..."Cures and therapies with curative intent are here in hepatitis C and are coming in other serious diseases. So everyone, from pharma suppliers patients, is scrambling to figure out what this means, writes Mike Rutstein.
Latest:
Big Data's Big Opportunity in ChinaBryan Spielman outlines why China is poised for a data renaissance-one that could play a pivotal role in the next wave of pharma innovation.
Latest:
Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.
Latest:
Blockbuster 2.0: Eight Ways to Follow that LeaderWhat can companies do for an encore when their own blockbuster product is threatened by branded or generic competitors?
Latest:
Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug AdherenceDrug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority
Latest:
Sales Personnel Contracts, Sword or Shield for M&A ValuationDetermining a company’s acquisition/merger value requires an intensive due diligence process. Attorney Gregg Metzger discusses salesforce contracts which, especially for life science companies, cannot be overlooked.
Latest:
Big Data Innovation and Risk: How to Strike the BalanceAs the industry continues to face declining R&D productivity, one efficient way of making the failure rate lower is to use data, writes Adam Towvim.
Latest:
Confronting the Post-Grant ThreatChallenges from investment firms to biopharma patents spur the industry to action to protect its drug franchises
Latest:
Towards Real-World Patient CentricityPatient centricity requires clinical trials to be based on life outside the lab, writes Mads Holme.
Latest:
Why Is It Such a Challenge to Treat PAH?Despite recent advances, there continue to be significant issues that compromise the effective management of pulmonary arterial hypertension, writes Victoria Allan.
Latest:
Divergent Paths: Pharm Exec Profiles Five Recent Drug LaunchesPharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Latest:
The Challenge of Forecasting BiosimilarsThe biosimilars market forecaster must create a framework that captures the dynamics that operate in these markets and do justice to the uncertainty and quantification of assumptions, writes Arthur G. Cook
Latest:
The Salix-Valeant Acquisition: "It’s Just a Game"Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition - how analysts and investors can affect decision-making and potentially drive poor behavior.
Latest:
Patient-centric innovation in packaging moves beyond regulatory requirements to deliver brand differentiation and increased salesNot so long ago, pharmaceutical brand managers considered drug packaging an afterthought. Today, packaging not only matters, it is quickly becoming one of the most important considerations in the growth and success of any drug product. Manufacturers now consider innovative, smart packaging that pleases patients in their new roles as consumers, and encourages brand loyalty to be a game changer in an increasingly competitive and crowded biopharmaceutical market.
Latest:
Europe Needs News Timeline for IDMP ImplementationAll indications are that the July 2016 deadline for transition from Europe's eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports.
Latest:
Resell vs. Direct Models: US Branded Drug Distribution in the FutureKathleen Iacocca and Yao Zhao discuss why direct supply chain models can be more sustainable than resell models in the long run and whether they can be implemented in the US.
Latest:
New Payment Models: It's Time to MoveCommercial success for pharma brands now demands proactive strategies and interventions
Latest:
New Payment Models: It's Time to MoveCommercial success for pharma brands now demands proactive strategies and interventions
Latest:
Why Patient-Centric Innovation Holds the Key to Long-Term Business Success for Companies in China’s Booming Biotech SectorAssessing the road ahead for Chinese biotech.
